6,678 trials
Alzheimer Dementia
Primary: Feasibility of a Virtual Multicrossover Randomized Control Trial Design as Measured my Completion Rates and Medication Compliance. — 7; 7; 7 Participants
Colonoscopy
Primary: Endoscopist Evaluation of Colon Cleanliness in the Lubiprostone Group vs the Placebo Group — 1.38; 1.24 score on a scale — p=0.05
Blood Loss · Blood Transfusion
Primary: Calculated Blood Loss — 842; 860; 799; 878 CBL (ml)
Pressure Injury
Primary: Number of Participants With Intraoperative Acquired Pressure Injuries (IAPI) — 13; 14 Participants
Neonatal Abstinence Syndrome
Primary: Length of Hospital Stay — 17.9; 16.1 days
Sexually Transmitted Diseases
Primary: Rectal Doxycycline Concentration — 0.654 µg/g
Idiopathic Parkinson Disease
Primary: Change From Baseline to Week 16 in Pain Severity (NRS-11 Scale) - Full Analysis Set — -1.6; -0.8 score on a scale — p=0.1695
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
Covid19 · SARS-CoV2 Infection
Primary: Neutralizing Antibody (NAb) Level — 2242.47; 2695.21; 2196.74; 888.80 titer
Diabetic Wound
Primary: Complete Wound Closure — 4; 7 Participants
Hypertension
Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001
Influenza
Primary: Innate Cell IFNa2a Production — 112.3650; 131.4214; 107.5846; 134.9071 pg/mL
Postoperative Pain
Primary: Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score — 16.7; 18.1 score on a scale
Coronary Artery Disease
Primary: Platelet Reactivity Measured by VerifyNow — 16.9; 12.6 P2Y12 reaction units
Asthma
Primary: Percentage of Participants Making at Least One Critical Error After Reading the Patient Information Leaflets (PIL) — 6; 26 Percentage of participants — p=<0.001